These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 20651347)

  • 1. Antiproliferative effects of antiestrogens and inhibitors of growth factor receptor signaling on endometrial cancer cells.
    Block M; Fister S; Emons G; Seeber S; Gründker C; Günthert AR
    Anticancer Res; 2010 Jun; 30(6):2025-31. PubMed ID: 20651347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of the AKT/mTOR and erbB pathways by gefitinib, perifosine and analogs of gonadotropin-releasing hormone I and II to overcome tamoxifen resistance in breast cancer cells.
    Block M; Gründker C; Fister S; Kubin J; Wilkens L; Mueller MD; Hemmerlein B; Emons G; Günthert AR
    Int J Oncol; 2012 Nov; 41(5):1845-54. PubMed ID: 22922893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17beta-estradiol and hydroxytamoxifen in endometrial cancer cells.
    Vivacqua A; Bonofiglio D; Recchia AG; Musti AM; Picard D; Andò S; Maggiolini M
    Mol Endocrinol; 2006 Mar; 20(3):631-46. PubMed ID: 16239258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nuclear estrogen receptor-mediated Notch signaling and GPR30-mediated PI3K/AKT signaling in the regulation of endometrial cancer cell proliferation.
    Wei Y; Zhang Z; Liao H; Wu L; Wu X; Zhou D; Xi X; Zhu Y; Feng Y
    Oncol Rep; 2012 Feb; 27(2):504-10. PubMed ID: 22075757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines.
    Festuccia C; Muzi P; Millimaggi D; Biordi L; Gravina GL; Speca S; Angelucci A; Dolo V; Vicentini C; Bologna M
    Endocr Relat Cancer; 2005 Dec; 12(4):983-98. PubMed ID: 16322337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 17 beta-estradiol- and 4-hydroxytamoxifen-induced transactivation in breast, endometrial and liver cancer cells is dependent on ER-subtype, cell and promoter context.
    Castro-Rivera E; Safe S
    J Steroid Biochem Mol Biol; 2003 Jan; 84(1):23-31. PubMed ID: 12648521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Perifosine inhibits growth of human experimental endometrial cancers by blockade of AKT phosphorylation.
    Engel JB; Honig A; Schönhals T; Weidler C; Häusler S; Krockenberger M; Grunewald TG; Dombrowski Y; Rieger L; Dietl J; Wischhusen J
    Eur J Obstet Gynecol Reprod Biol; 2008 Nov; 141(1):64-9. PubMed ID: 18687514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Growth and activation of PI-3K/PKB and Akt by stromal cell-derived factor 1alpha in endometrial carcinoma cells with expression of suppressor endoprotein PTEN.
    Li XP; Zhao D; Gao M; Zhao C; Wang JL; Wei LH
    Chin Med J (Engl); 2006 Mar; 119(5):378-83. PubMed ID: 16542580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GPER mediates the Egr-1 expression induced by 17β-estradiol and 4-hydroxitamoxifen in breast and endometrial cancer cells.
    Vivacqua A; Romeo E; De Marco P; De Francesco EM; Abonante S; Maggiolini M
    Breast Cancer Res Treat; 2012 Jun; 133(3):1025-35. PubMed ID: 22147081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The G protein-coupled receptor GPR30 mediates the nontranscriptional effect of estrogen on the activation of PI3K/Akt pathway in endometrial cancer cells.
    Ge X; Guo R; Qiao Y; Zhang Y; Lei J; Wang X; Li L; Hu D
    Int J Gynecol Cancer; 2013 Jan; 23(1):52-9. PubMed ID: 23235274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. lncRNA LA16c‑313D11.11 modulates the development of endometrial cancer by binding to and inhibiting microRNA‑205‑5p function and indirectly increasing PTEN activity.
    Xin W; Zhao S; Han X; Zhao P; Yu H; Gao X; Li P; Wu Q; Ding J; Hua K
    Int J Oncol; 2020 Jul; 57(1):355-363. PubMed ID: 32319598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selenium disrupts estrogen receptor (alpha) signaling and potentiates tamoxifen antagonism in endometrial cancer cells and tamoxifen-resistant breast cancer cells.
    Shah YM; Al-Dhaheri M; Dong Y; Ip C; Jones FE; Rowan BG
    Mol Cancer Ther; 2005 Aug; 4(8):1239-49. PubMed ID: 16093440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estrogen receptor-dependent and estrogen receptor-independent pathways for tamoxifen and 4-hydroxytamoxifen-induced programmed cell death.
    Obrero M; Yu DV; Shapiro DJ
    J Biol Chem; 2002 Nov; 277(47):45695-703. PubMed ID: 12244117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Akt down-modulation induces apoptosis of human prostate cancer cells and synergizes with EGFR tyrosine kinase inhibitors.
    Festuccia C; Gravina GL; Muzi P; Millimaggi D; Dolo V; Vicentini C; Bologna M
    Prostate; 2008 Jun; 68(9):965-74. PubMed ID: 18361408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential effects of estrogen and antiestrogen on transforming growth factor gene expression in endometrial adenocarcinoma cells.
    Gong Y; Ballejo G; Murphy LC; Murphy LJ
    Cancer Res; 1992 Apr; 52(7):1704-9. PubMed ID: 1551100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro.
    Gee JM; Harper ME; Hutcheson IR; Madden TA; Barrow D; Knowlden JM; McClelland RA; Jordan N; Wakeling AE; Nicholson RI
    Endocrinology; 2003 Nov; 144(11):5105-17. PubMed ID: 12960029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors.
    Philip CA; Laskov I; Beauchamp MC; Marques M; Amin O; Bitharas J; Kessous R; Kogan L; Baloch T; Gotlieb WH; Yasmeen A
    BMC Cancer; 2017 Sep; 17(1):638. PubMed ID: 28886696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of estrogen on the proliferation of endometrial cancer cells is mediated by ERRγ through AKT and ERK1/2.
    Sun Y; Wang C; Yang H; Ma X
    Eur J Cancer Prev; 2014 Sep; 23(5):418-24. PubMed ID: 25068805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
    McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
    Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. JQ1 suppresses tumor growth via PTEN/PI3K/AKT pathway in endometrial cancer.
    Qiu H; Li J; Clark LH; Jackson AL; Zhang L; Guo H; Kilgore JE; Gehrig PA; Zhou C; Bae-Jump VL
    Oncotarget; 2016 Oct; 7(41):66809-66821. PubMed ID: 27572308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.